RxDoctor Payments DataLook up a doctor →

Keith Friedman, MD

Cardiovascular Disease · Columbia, MDNPI 1194793877

Payments from drug & device makers

$1,210,337in general payments, 2019–2025

Across 415 payments — averaging $2916.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$423K
  • Amgen$304K
  • Boehringer Ingelheim International GmbH$133K
  • Esperion Therapeutics, Inc.$92K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$76K
  • Bayer$65K
  • plus $117K from 6 others

General payments by program year

19
20
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,210,337 in reported general payments places this provider in the 95th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland

Medicare billing

Part B allowed, 2024
$404,565
Medicare patients
2,120
Services billed
4,933

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Columbia

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →